Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FSQS7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,792
Award facts
- Contract value 100% obligated
- $15,792.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $15,792.20 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes, awarded on January 26, 2026, with an ultimate completion date of February 17, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order utilizes a firm fixed-price contract structure and will be performed at the company's Park Ridge location.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract valued at $499.999 billion through December 31, 2036. The PPV-G GEN V program represents part of a broader $30.3 billion federal acquisition strategy designed to supply pharmaceutical products and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's authorization to supply specialized biologics such as XOLAIR reflects its established role as a critical pharmaceutical supplier supporting Department of Defense healthcare operations globally, with the company demonstrating substantial performance capability across diverse therapeutic categories and product lines.
Quick answers
Who was awarded contract SPE2DR26FSQS7?
SPE2DR26FSQS7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FSQS7 worth?
The government has obligated $15,792 on SPE2DR26FSQS7.
Is contract SPE2DR26FSQS7 an order under another contract?
Yes. SPE2DR26FSQS7 is a delivery order under SPE2DR25D9348, an indefinite delivery contract.
Was contract SPE2DR26FSQS7 competed?
The extent of competition for SPE2DR26FSQS7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award